Taken together with dozens of other fines the EU has imposed on American tech firms, last week’s action against Google was further confirmation that the DMA functions less as a competition tool than as an extractive mechanism. The difference this time is that the Trump administration sent a clear signal it won’t stand for this anymore.

Adversarial AI distillation poses a growing threat to U.S. AI leadership and national security, and Congress is right to address it through the Deterring American AI Model Theft Act (DAAMTA). But before passing the bill, lawmakers should narrow its scope, strengthen evidentiary standards, protect legitimate research, and pair it with technical safeguards and international cooperation to better combat large-scale AI model theft without hindering innovation.

Waiting for the next Congress is the wrong approach. Because neither party can pass a federal privacy law without bipartisan support, lawmakers should build on the SECURE Data Act's bipartisan, state-tested framework to enact a national privacy law that protects consumers and the economy.

Applying Most Favored Nation pricing to both Medicare and Medicaid—requiring U.S. prices for drugs that have already been launched to equal the lowest prices among a group of peer countries—is estimated to reduce U.S. pharmaceutical revenues by 49 percent and global pharmaceutical revenues by 31 percent.

The USMCA’s digital trade rules set the global standard. Now, policymakers should modernize them for the age of AI, close loopholes that enable data localization and discriminatory taxes, and build a more secure, competitive North American digital economy.

The App Store Freedom Act would impede innovation, weaken U.S. technological leadership, and import a hostile antitrust framework used abroad to discriminate against American technology companies.

The FDA is considering allowing seven unapproved peptides—substantially sourced through a Chinese gray market—to be used by U.S. compounding pharmacies, despite its own scientists warning against it. Approving them would legitimize unvetted foreign suppliers and undermine evidence-based drug regulation.

Both small and large firms are essential to America’s innovation system because they specialize in different forms of innovation. Congress should double the regular R&D tax credit to 40 percent and reduce the red tape associated with claiming it.

Manufacturing labor productivity growth is a key driver of the United States’ long-term economic performance and global competitiveness, but it has slowed sharply since 2005. Congress should provide a 25 percent tax credit to firms adopting productivity-enhancing technologies to help reverse this slowdown.

German exports to China as a share of GDP have declined by more than 40 percent since 2021, while the German labor force has seen a decline of more than 400,000 jobs linked to exports to China.